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DISCUSSION AND ROUND TABLE PRESENTATION
Chairman Terblanche: Most of the discussion time will be spent reviewing the
long-term management of patients after a variceal bleed. In the last 10 minutes we
will attempt to place the role of prophylactic therapy in perspective.
In my view there are some end-stage patients who should not be subjected to
either emergency or definitive treatment. Unfortunately they are frequently diffi-
cult to identify as even apparently poor risk patients may well improve their liver
status if they recover from the bleeding episode. There is also evidence to suggest
that the risk of recurrent bleeding and death rapidly diminishes as time passes after
a bleeding episode, with this risk returning to baseline within two to three months.
I believe that continued non-specific medical management alone is an option that
should be considered in some otherwise fit patients who survive a single episode of
variceal bleeding. This would allow one to determine whether they fall into the
30% of so of patients who will not have a further bleed. However, I concede that
the majority of patients who have had a variceal bleed do require further therapy to
prevent the next variceal bleed.
All of the panelists have agreed that repeated injection sclerotherapy is the most
widely used form of therapy and emphasised the "need to identify those patients
who should be considered as failures of sclerotherapy. Such patients should be
subjected to a surgical salvage procedure, either a shunt or a devascularisation and
transection operation. The views of the panel differ on the exact criteria to be used
and which patients should be subjected to operation. Bornman first drew attention
to the fact that two sclerotherapy failures during a single hospital admission for an
acute variceal bleed was associated with a prohibitive mortality in Child’s category
B and C patients and that such patients should be subjected to early surgical
therapy2. Will the panel please define the current role of sclerotherapy and how
they would identify sclerotherapy failures.
Panelist Paquet: Concerning the chairman’s first statement that there are some
patients who should not be subjected to either emergency or definitive treatment, I
propose that emergency and definitive treatment should be separated. From my
point of view, every patient with uncontrollable variceal haemorrhage needs emergency
treatment as early as possible. This immediate endoscopic sclerosis should prefera-
bly be performed in centers with expertise. Otherwise, the patients should be
transferred to such a center with a balloon tube in place. With this therapeutic
strategy the results of emergency treatment of bleeding oesophageal varices using
oesophageal balloon tamponade or immediate endoscopic injection sclerosis can be
improved as has been demonstrated by our group and others3-5. If emergency
injection sclerotherapy is not successful, patients should immediately undergo an
emergency devascularisation procedure particularly if they are in the Child C
group.
Since 1975 we have taken two early or long-term recurrences of oesophageal
variceal hemorrhage or one recurrence of gastric variceal bleeding as an indication
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for surgical procedure. We try to stop oesophageal variceal bleeding again a second
time by emergency sclerotherapy. In Child A and B patients we prefer a distal
splenorenal or a narrow lumen mesocaval interposition shunt one to three weeks
later. Additional selection criteria are liver volume (1000-2500ml) measured
sonographically; portal perfusion (more than 10%) investigated by sequential
scintigraphy; and exclusion of activity or progression of the liver cirrhosis or a
stenosis of the arterial supply to the liver by laparoscopy and angiography
respectively. We have demonstrated that these shunt procedures are the best form
of treatment for bleeding oesophagogastric varices resistant to early and long-term
endoscopic sclerotherapy6.
Panelist Henderson: Sclerotherapy is the first line management for acute variceal
bleeding, and ideally should be performed at the time of the first diagnostic
endoscopy. Its role in the prevention of recurrent bleeding is less clear. Current
data show sclerotherapy to have equal efficacy with beta-blockade, an overall long-
term rebleeding rate in excess of 50%, and a "failure rate" of 25% 30%. I would
define sclerotherapy failure as rebleeding which cannot be controlled by repeated
sclerotherapy. Rather than a set number of bleeding episodes or units of blood, the
overall bleeding pattern should be considered. Three minor bleeding episodes over
3 years may be acceptable, while one massive rebleed from gastric varices is clearly
a failure. In summary, I would advocate chronic sclerotherapy as the initial therapy
to prevent rebleeding and use the time it buys to define the severity of the
underlying liver disease.
Panelist Idezuki: It is true that sclerotherapy has become the first choice treatment
for control of acute bleeding from varices in many institutions. In some of the
patients varices disappear completely after a few sclerotherapy treatment sessions
and never recur. However, it is also true that in many of the patients varices and
bleeding do recur after this modality of treatment. From our experience, we feel
that if the initial 3 to 4 sclerotherapy treatments fail to improve the grade of varices
to red-color sign negative and F1, it is often difficult to eradicate varices by
sclerotherapy even if we continue further sessions of sclerotherapy. In these
patients, we recommend operative treatment; that is oesophageal transection and
extensive devascularisation with splenectomy in our department.
Panelist Bornman: Sclerotherapy is currently our first line of therapy for all
patients admitted with proven oesophageal variceal bleeding. Only failures of
sclerotherapy during the acute phase, as defined by two recurrent bleeding episodes
during the same admission, are considered for salvage surgery. We prefer to do a
simple transection of the oesophagus using an EEA staple gun. If this is not
technically feasible, a standard end-to-side portacaval shunt or an eight millimeter
interposition Gortex graft (Sarfeh Shunt) would be our second choice.
Long-term sclerotherapy failures are more difficult to define. The number of
injection sessions and the duration taken to eradicate varices are not an accurate
measure of success and even patients with persistent small varices often do well
with no further bleeding. We are more concerned about patients who develop
recurrent life-threatening bleeds during the phase before varices are eradicated or
when this occurs with recurrent varices after initial successful variceal obliteration.ROUND TABLE PRESENTATION 41
So far, we have been unable to identify patients who will respond poorly to long-
term repeated sclerotherapy.
Chairman Terblanche: Thank you. That gives us a reasonable consensus, although
there are some differences of opinion. If I can summarise: repeated injection
sclerotherapy is the most widely used treatment in the initial long-term manage-
ment of patients after a proven variceal bleed, with some form of surgery being
reserved as a salvage procedure. Dr Henderson, you indicated in your presentation
that the alternative to repeated injection sclerotherapy is long-term pharmacologi-
cal therapy with beta blockade. I believe that this is still controversial and at the
investigative level. The problems with beta blockade with propran.olol include the
need for continued long-term therapy with more than one dose a day, as well as the
highly unlikely situation of obtaining complete patient compliance, particularly in
alcoholic cirrhotic patients. There is some evidence to suggest that propranolol
therapy might be helpful in the early phase after a variceal bleed to reduce
recurrent bleeding while varices are being eradicated with sclerotherapy. An even
more intriguing suggestion comes from a Danish group who propose that the
combination of propranolol with sclerotherapy leads to more effective eradication
of varices. They have shown that, in the short term, this combination reduces
recurrence of oesophageal varices and bleeding after variceal obliteration7. There is
also some evidence to suggest rebound bleeding may occur in patients who stop
taking propranolol. Dr Henderson, would you like to put the case for long-term
medical therapy?
Panelist Henderson: I find myself in the unusual position of being a surgeon and
advocating a nonsurgical therapy. But we cannot ignore the data. Portal hyperten-
sion can be reduced pharmacologically and beta-blockade is only the first of what I
feel sure will be other effective pharmacological therapy. While the case has clearly
been substantiated for the use of propranolol (or long acting nadolol) in the
prophylaxis of variceal bleeding, the data are conflicting on the use of beta-
blockade to prevent recurrent bleeding8’9. Eleven randomized trials comparing
beta-blockers to controls have shown an overall significant reduction in rebleeding
from 67% to 39%, but no significant effect on mortality. Five randomized trials
comparing beta-blockers to sclerotherapy have shown a 48% overall rebleeding
rate in both groups, and mortalities of 32% and 30% repectively. I believe that if
we accept the efficacy of sclerotherapy as a therapeutic modality in prevention of
rebleeding, we must also accept beta-blockade as equally good.
Chariman Terblanche: Any other panelist?
Panelist Idezuki: We have no experience with propranolol. However, measuring
intravariceal pressure and blood flow during sclerotherapy, we have found that
varices with low pressure and low flow are more easily eradicated by sclerotherapy
than those with higher pressure and high flow. It is possible that the use of
propranolol in conjunction with sclerotherapy may be helpful.
Panel&t Paquet: Our group could not confirm the results of the Kings College
group
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propranolol. Metipranolol was administered 3 times per day (10 20 mg) reducing
the heart rate by at least 25%. We were not able to reduce the frequency of
recurrence of haemorrhage when at least one phase of endoscopic sclerotherapy
was completed and the varices were reduced in size and protected by scar tissue11.
However, it must be underlined that the timing of the administration of beta
blockers differed from that of the Kings College group. They administered the drug
directly after the first session of sclerotherapy and continued treatment until the
varices were eradicated. Our patients took the drug after at least one phase of
sclerotherapy (usually three to five sessions) or sometimes even two phases of
sclerotherapy were finished and while they were waiting for the subsequent
endoscopic sclerotherapy, usually performed after three or four months.
Chairman Terblanche: I believe that in the future we may well have other forms of
medical management where a single daily dose of a relatively safe agent may make
long-term medical therapy more attractive than it is at present. Despite Dr
Henderson’s comments, I believe that long-term medical therapy should only be
undertaken in an expert centre under careful control and guidance.
I did not hear any of the panelists present a case for utilizing major surgical
procedures, such as shunts or transection and devascularisation operations, in all
patients. If this is agreed could I ask each of the panelists to again shortly
summarise how they set about selecting patients for their favourite procedure after
sclerotherapy has failed. Each has indicated this briefly in their papers but I believe
it would be useful to attempt to arrive at some consensus.
Panelist Bornman: We prefer a devascularisation and oesophageal transection
procedure for sclerotherapy failures, but in some patients this is not possible
because of extensive peri-oesophageal fibrosis from repeated injection sclerother-
apy sessions. Therefore, all patients undergo portography prior to surgery, in case a
shunt procedure is required. In such cases we prefer a selective shunt for good risk
patients and a standard portacaval shunt for poor risk alcoholic cirrhotic patients.
However, an appreciable number of our sclerotherapy failures have end-stage liver
disease and in these patients active treatment is withdrawn.
Panelist Paquet: Again, I repeat that we define "sclerotherapy failure" as either
two early or late recurrences of oesophageal variceal bleeding during the course of
endoscopic sclerotherapy, or one recurrent haemorrhage from gastric varices. Our
favoured surgical procedure during the emergency situation, particularly in Child C
patients, is a gastro-oesophageal disconnection (with or without splenectomy or
fundoplication) and in cases with portal pressure over 40 cm of water, an
emergency mesocaval shunt. During the bleeding free interval a distal splenorenal
or a narrow lumen mesocaval interposition shunt is performed according to the
above-mentioned criteria in Child’s A and B patients.
Panelist Henderson: I would emphasise that I believe the choice of surgical
procedure when sclerotherapy fails is dictated by the acuteness of bleeding and the
severity of the liver disease. In my repertoire: i) the occasional patient with massive
continued bleeding despite sclerotherapy will receive a large bore mesocaval shunt:
ii) my most common surgical rescue is distal splenorenal shunt, which I believe
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iii) liver transplantation should be considered for suitable candidates with end-stage
liver disease.
Panelist Idezuki: As I have already mentioned, transection and devascularisation
procedures can be performed safely without significant mortality and morbidity in
patients of ChildA and B categories. So we recommend these major procedures for
patients in these categories who are under the age of 65. However, we have now
stopped operating on Child C patients, and patients complicated with unresectable
hepatoma. Also, we recommend continued sclerotherapy if the patient’s age is over
65 years.
Chairman Terblanche: Clearly, controlled trials are going to help us achieve better
definitions of which patient should be subjected to either a shunt or a devascularisa-
tion and transection operation. May I remind you that the preliminary data
presented by David Triger from the Multicentre United Kingdom trial has shown
that surgery does not confer appreciable benefit when comparing oesophagogastric
devascularisation and transection with endoscopic sclerotherapy in long-term
management. Portacaval shunt trials have provided conflicting data. I accept the
Atlanta proposal that sclerotherapy be the primary therapy with shunt salvage (or
devascularisation and transection salvage) being used for those patients who are
considered failures. Long-term treatment failure should be considered either when
patients continue to have repeated bleeds despite sclerotherapy or when the
oesophageal varices are difficult to eradicate. Major surgery, unfortunately, has to
be restricted to the Child’s A and B group patients and to the better risk Child’s C
patients. Poor risk end-stage Child’s C patients should not be subjected to elective
surgery, other than an hepatic transplant when indicated.
The use of narrow lumen shunts, either portacaval or mesocaval, has been
alluded to by both Dr Paquet and Dr Idezuki. It was Henri Bismuth who first
suggested narrowing the diameter of a shunt. The leader in narrow lumen shunts
has been Sarfeh who has clearly emphasized the role of narrow diameter reinforced
portacaval shunts. Would the other two panelists like to comment on their views on
the current role of narrow lumen shunts combined with devascularisation and
compartmentalisation operations?
Panelist Henderson: My conversion to accepting a potential role for narrow lumen
shunts comes from data in the propranolol studies, which show that reduction of
hepatic venous pressure gradient to 12 mm Hg or less prevents variceal bleeding.
This figure is identical to that defined by Dr Sarfeh with an 8 mm shunt in his
careful haeomodynamic studies. I think more data may support their use.
Panelist Bornman: The narrow lumen interposition shunt is an attractive option by
virtue of its simplicity but we would consider this operation as a salvage procedure
only at this stage during the acute bleeding episode. One would like to see more
long-term patency results before advocating this as a definitive shunt procedure for
good risk patients.
Chairman Terblanche: When we consider shunts in otherwise fit patients in 1990
then the main options are the distal splenorenal shunt or a narrow lumen shunt with
disconnection. I note that there is agreement from all the panelists.44 J. TERBLANCHE
Chairman Terblanche: There appear to be several devascularisation and transec-
tion operations available for long-term management. In Cape Town we use a
procedure similar to that described by Dr Paquet, namely, extensive upper gastric
and lower oesophageal devascularisation with an oesophageal stapled transection
without splenectomy. We are currently conducting a controlled trial comparing this
treatment with sclerotherapy. We perform a highly selective vagotomy along the
lesser curve of the stomach and disconnect the short gastric vessels from the spleen,
leaving the spleen in situ, and then devascularise the lower 6 to 7 cm of the
oesophagus prior to transecting the oesophagus. We currently combine this with a
fundoplication. In some patients we have noted large perforating veins entering the
oesophagus relatively high up and I believe that one needs to look for these
perforators very carefully. Today, devascularisation without transection has been
largely abandoned on the basis of the long-term results of the studies in patients,
other than those with schistosomiasis. In patients who have had devascularisation
and transection procedures, if varices recur, they can usually be relatively easily
and successfully treated with subsequent sclerotherapy. The recurrence rate after
devascularisation and transection operations appears to be higher than after
shunting. Do any of the panelists wish to comment?
Panelist Idezuki: We are still doing extensive devascularisation without transection
of the oesophagus in patients whose varices are limited to the region of cardia of the
stomach and also in acute bleeders who fail with sclerotherapy treatment.
It is not safe to transect the oesophagus where the inflammatory process, which
is caused by injection of sclerosants, is still active and in these cases we only
perform extensive devascularisation and splenectomy. Residual varices after devas-
cularisaion can usually be treated easily by sclerotherapy.
Regarding the recurrence rate of varices after transection and devascularisation,
it may be slightly higher than after shunt operations but recurrent bleeding has
been around 7% which we consider to be acceptable.
Chairman Terblanche: I believe that there is geheral consensus on the panel that
hepatic transplantation should be considered in all patients who present with a
variceal bleed but that only a very small percentage of our patients will ultimately
qualify for a liver transplant. In those who are likely to be transplant recipients,
sclerotherapy and/or drug therapy would be the initial treatment of choice. For the
failures of sclerotherapy, a transection with or without devascularisation would be
preferable to a shunt and if a shunt is performed, a narrow diameter reinforced
PTFE mesocaval graft would be preferable to a portacaval shunt. Several groups
have indicated that liver transplantation is perfectly feasible and can be performed
with reasonable safety after a previous portacaval shunt, but this does increase the
technical difficulty of the operation. Do the panelists agree?
Panelist Henderson: A potential liver transplant patient who fails sclerotherapy
when their own liver still has 2 to 5 years of life in it should have a distal splenorenal
shunt. A mesocaval shunt should be used as a life saving (stop bleeding) operation
in a patient who may come to early transplant. These two procedures are more
remote from the operative field for transplantation than a transection/
devascularisation procedure. I do not personallyfavour the latter as I believe they
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Chairman Terblanche: I would now like to turn to prophylaxis or therapy in
patients who have portal hypertension and varices but who have not yet had a
variceal bleed. It would perhaps we helpful if I was to provide a brief overview of
my own throughts and then ask the panelists to comment.
My views on prophylactic therapy have been clearly stated in the literature and
have not changed in 199012 Options in prophylactic therapy include the following.
One is to undertake no specific therapy and wait until the first bleed occurs. This is
the option that I believe should be followed in 1990 because it has been clearly
demonstrated that the majority of patients do not bleed prior to their death from
liver failure if they have not had a previous bleed. Estimates vary, but between
70% and 80% of patients will not bleed. Under these circumstances 70% to 80% of
patients would be receiving any prophylactic therapy used unnecessarily. This is
unjustified. The problem has been to identify patients at high risk of a variceal
bleed and only subject them to prophylactic therapy. Both the Japanese group of
Dr Idezuki and the German group of Dr Paquet appear to have identified a high
risk group of patients, but I would like to hear their views. I believe that
prophylactic therapy remains unjustified outside of major centers or controlled
trials at this time. The most important information on the identification of high risk
patients comes from the North Italian Endoscopic Club who have utilized three
separate factors in formulating their index of a high probability of a first variceal
bleed. These factors are the clinical Child’s class of the patient; the size of the
varices; and the presence of red wale markings. They have been able to identify a
subset of patients at very high risk of bleeding 13. If this is confirmed by other groups
then some form of prophylaxis, particularly prophylactic drug therapy, may well
become indicated. A recent meta-analysis from Edinburgh of the value of propra-
nolol in the prevention of variceal haemorrhage comes out in favour of propranolol
for primary prevention of variceal haemorrhage in patients with large varices9.
Panelist Henderson: I believe that prophylactic propranolol therapy is justified in
patients who have varices identified. The data persuade me that this will reduce the
risk of their initial bleed by 50%. I agree that it may only be a delay, but I think it is
justified and worthwhile.
Prophylactic sclerotherapy is not justified by current data. Better definition of
higher risk groups, such as the work being done by NIEC may change this.
Surgical prophylaxis has resurfaced in 1990 with the Japanese multi-center study
of portal nondecompressive surgery which shows a significant survival advantage to
the operated group. I do not believe this should be generally advocated, but it does
warrant further study.
Panelist Paquet: The aim of long-term prophylactic treatment of cirrhotics with
oesophageal varices is to prevent the first episode of variceal haemorrhage and
thereby improve survival. Only one-third of patients with cirrhosis and varices are
thought to be likely to bleed. If all patients with cirrhosis and varices were treated
prophylactically, two-thirds will be managed unnecessarily. Thus, prophylactic
sclerotherapy is only justified in one-third of all cirrhotics with portal hypertension.
Furthermore, in many studies the bleeding risk of this third can be estimated by the
following risk factors: 1. Large varices (degree III to IV), according to our
classification; 2. Appearance of the varices telangiectasis or cherry red spots on
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pressure over 22 mmHg. In a prospective controlled randomized trial, 61 consecu-
tive patients from a group of 232 were selected for prophylactic endoscopic
sclerotherapy or as controls. If bleeding occurred in control patients, the therapy of
choice was endoscopic sclerotherapy. The frequency of variceal haemorrhage in the
control group was 74% (23 patients) and 30% (10 patients) in the sclerotherapy
group. Death after a median follow up of 14 months was 62% (20 patients) in the
controls and 20% (6 patients) in the sclerotherapy group. Thus sclerotherapy was
more efficient in preventing first bleeding and prolonging survival in selected
cirrhotic patients with a high risk of variceal haemorrhage, particularly Childs A
and B patients. Only in this highly selected group is prophylactic endoscopic
sclerotherapy justified.
Panelist Idezuki: I have already presented our data on prophylaxis in the paper. I
would only like to point out that the number of patients undergoing prophylactic
surgery in Japan has decreased considerably since the development of sclerother-
apy, and now patients who have risky varices are treated by prophylactic scleroth-
erapy. We may concede that some of these patients may not have bled during their
lifetime and prophylactic treatment may not have been necessary and that we are
overtreating these patients. But at the same time no one can yet predict who is
going to bleed and when it will happen. Some of these patients may die from the
first bleeding episode, if the proper treatment is not available and initiated
immediately. If we consider this risk and if we can treat varices with less invasive
methods, without any risk, there may be a place for prophylactic treatment.
Chairman Terblanche: Thank you, What is your view Dr Bornman?
Panelist Bornman: I agree.
Chairman Terblanche: In concluding this symposium I would like to thank the
panelists for their wonderful co-operation. I believe that we have been able to place
the long-term management of varices in perspective, particularly in patients after a
previous variceal bleed. We also appear to have reasonable consensus on the
current situation with regard to prophylactic therapy. The audience might like to
note that in the July 1990 issue of the American Journal of Surgery, our panelist
Mike Henderson has assembled papers from most of the world’s experts in a special
commemorative issue dedicated to Dr W Dean Warren. Thank you all for your
participation.
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